In gastric cancer, MYBL2 activated ubiquitin-conjugating enzyme E2 C (UBE2C), leading to cisplatin resistance and cancer progression based on downregulated apoptosis and DNA damage response[48]. Here, MYBL2 is linked to gastric cancer.